PreOmics develops and produces innovative technologies for the pre-analytics of samples for mass spectrometry. Today, the processing of samples for mass spectrometry is usually carried out according to homemade protocols. These processes are slow, not reproducible, not robust and cannot be automated. These solutions are therefore very time-consuming and costly, which can lead to the loss of valuable samples.
PreOmics addresses these problems with a standardized technology that enables robust and reproducible results in sample preparation. In addition, the protocols have a significantly reduced workload compared to conventional methods. As part of the seed investment with High-Tech Gründerfonds and Business Angels, the first products were launched on the market and new products developed. The founders Garwin Pichler and Nils Kulak established a team in the facilities of the IZB in Martinsried and formed partnerships for production and further development. Think Health Ventures is now leading another financing round of 3.3 million euros to support the further internationalization of the business and the development of further products.
Dr. Garwin Pichler, Managing Director at PreOmics: “Customers worldwide use our technologies that enable standardized and efficient sample preparation for protein analysis and offer a significant cost-benefit advantage. With the new capital, we want to accelerate the expansion of our global distribution with a focus on the USA and the development of new products”.
Dr. Fabian Mohr, Investment Manager at HTGF: “We are very excited to be investing in Series A to continue the success of the Seed Round. The company has made a great development and we rely on the leadership team for further market expansion and product development.
For Dr. Michael Ruoff, Partner at Think Health Ventures, “the effective solution of a clear problem with positive market feedback combined with the expertise and ambition of the entire team” was essential for the investment. “With PreOmics, we see great potential to accelerate drug development for serious diseases, as PreOmics’ products currently have a second-to-nonemarket position.